Mariana Pinto
September 20, 2026

Owlpharma Celebrates 13 Years of Growth, Trust and Evolution

Thirteen years ago, Owlpharma was born from the vision and determination of its founders, César and Ricardo. What started as an ambitious idea quickly gained the trust of others who shared the same purpose and chose to become part of this journey.

Year after year, the team grew, bringing together new expertise, perspectives and experiences. With that growth came new challenges, more ambitious projects and the ability to embrace increasingly complex opportunities. At every stage, Owlpharma has continued to move forward with the same drive to evolve, innovate and go further.  

Looking back, César and Ricardo describe Owlpharma’s first year with a single word: overcoming. Today, thirteen years later, the word that best describes the company is solidity. Together, these two words capture a journey defined by resilience, sustainable growth and the trust placed in us by our clients, partners and team.

Over the years, Owlpharma has established itself as a trusted consultancy partner in Portugal’s pharmaceutical sector, while also taking its first steps beyond national borders. By continuously expanding its expertise and service offering, the company has strengthened its ability to support clients in an ever-evolving industry and take on new challenges with confidence.  

As we celebrate our 13th anniversary, we take pride in everything we have achieved together, while remaining focused on the future. Because thirteen years later, we still believe that evolution has no finish line.

To everyone who has been part of our story, thank you for making this journey possible.

13 Years of Expertise. Still Evolving.

Latest news

September 20, 2026

/

Mariana Pinto

Owlpharma Celebrates 13 Years of Growth, Trust and Evolution

September 17, 2026

/

Ana Rita Cordeiro

New Revision of GVP Module III: Key Updates in EU Pharmacovigilance Inspections

August 5, 2026

/

Matilde Gil

PPWR: Key Changes and Implementation Milestones for the Pharmaceutical and Medical Device Sectors